Safety profile and tolerability of antiangiogenic agents in nonsmall-cell lung cancer

Clinical Lung Cancer

Volumn 13, Issue 2, 2012, Pages 96-106

  Gadgeel, Shirish M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Antiangiogenic agents; Bevacizumab; Nonsmall cell lung cancer; Safety; Tolerability

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; GEMCITABINE; NINTEDANIB; PACLITAXEL; PEMETREXED; PLACEBO; SORAFENIB; SUNITINIB; VADIMEZAN;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC THERAPY; APPETITE; ARTERY THROMBOSIS; ARTHRALGIA; ASTHENIA; BLEEDING; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONSTIPATION; COUGHING; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIVERTICULITIS; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; DYSPHONIA; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEADACHE; HEMOPTYSIS; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; INFECTION; INJECTION SITE BURNING; INJECTION SITE PAIN; ISCHEMIA; LEUKOPENIA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PAIN; PREDICTION; PROTEINURIA; PRURITUS; RASH; RESPIRATORY TRACT DISEASE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; SAFETY;

EID: 84857428285     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.08.006     Document Type: Review

References (85)

1. A. Jemal, R. Siegel, J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. Non-Small Cell Lung Cancer National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-v.2.2010 National Comprehensive Cancer Network [Web site] http://www.nccn.org/professionals/physician-gls/PDF/nscl.pdf Accessed: April 8, 2010
3. O.S. Breathnach, B. Freidlin, B. Conley Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results J Clin Oncol 19 2001 1734 1742 (Pubitemid 32230875)
4. D.N. Carney Lung cancertime to move on from chemotherapy N Engl J Med 346 2002 126 128
5. D. Hanahan, J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364 (Pubitemid 26272076)
6. R.S. Kerbel Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312 2006 1171 1175 (Pubitemid 43801134)
7. D.H. Johnson, L. Fehrenbacher, W.F. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191 (Pubitemid 41095154)
8. S.R. Nalluri, D. Chu, R. Keresztes Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 300 2008 2277 2285
9. S. Hapani, D. Chu, S. Wu Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis Lancet Oncol 10 2009 559 568
10. X. Zhu, K. Stergiopoulos, S. Wu Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis Acta Oncol 48 2009 9 17
11. ® (bevacizumab) [package insert] Solution for intravenous infusion 2011 Genentech, Inc. South San Francisco, CA
12. E. Gore, A. Currey, N. Choong Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy J Thorac Oncol 4 2009 1590 1591
13. B. Goodgame, N. Veeramachaneni, A. Patterson Tracheo-esophageal fistula with bevacizumab after mediastinal radiation J Thorac Oncol 3 2008 1080 1081
14. D.R. Spigel, J.D. Hainsworth, D.A. Yardley Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab J Clin Oncol 28 2010 43 48
15. M. Kreuter, M. Kropff, A. Fischaleck Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment Eur Respir J 33 2009 1383 1388
16. A.P. Meert, M. Paesmans, B. Martin The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 87 2002 694 701 (Pubitemid 35178743)
17. N. Weidner Intratumor microvessel density as a prognostic factor in cancer Am J Pathol 147 1995 9 19
18. J. Folkman, M. Klagsbrun Vascular physiology A family of angiogenic peptides Nature 329 1987 671 672
19. J. Folkman, Y. Shing Angiogenesis J Biol Chem 267 1992 10931 10934
20. A. Yuan, C.-J. Yu, S.-H. Kuo Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer J Clin Oncol 19 2001 432 441 (Pubitemid 32112856)
21. B. Millauer, M.P. Longhi, K.H. Plate Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo Cancer Res 56 1996 1615 1620 (Pubitemid 26104026)
22. J.G. Beitz, I.S. Kim, P. Calabresi Human microvascular endothelial cells express receptors for platelet-derived growth factor Proc Natl Acad Sci U S A 88 1991 2021 2025
23. R.H. Alvarez, H.M. Kantarjian, J.E. Cortes Biology of platelet-derived growth factor and its involvement in disease Mayo Clin Proc 81 2006 1241 1257 (Pubitemid 44316290)
24. E. Bergsten, M. Uutela, X. Li PDGF-D is a specific, protease-activated ligand for the PDGF β-receptor Nat Cell Biol 3 2001 512 516 (Pubitemid 32422089)
25. K. Pietras, K. Rubin, T. Sjoblom Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy Cancer Res 62 2002 5476 5484
26. A. Levitzki PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases Cytokine Growth Factor Rev 15 2004 229 235 (Pubitemid 38781048)
27. J. Dong, J. Grunstein, M. Tejada VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis EMBO J 23 2004 2800 2810 (Pubitemid 39013552)
28. E. Brogi, T. Wu, A. Namiki Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only Circulation 90 1994 649 652 (Pubitemid 24242728)
29. G. Bergers, S. Song, N. Meyer-Morse Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J Clin Invest 111 2003 1287 1295 (Pubitemid 36554699)
30. R. Erber, A. Thurnher, A.D. Katsen Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms FASEB J 18 2004 338 340
31. M. Murakami, Y. Zheng, M. Hirashima VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment Arterioscler Thromb Vasc Biol 28 2008 658 664 (Pubitemid 351651323)
32. M. Rusnati, M. Presta Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies Curr Pharm Des 13 2007 2025 2044 (Pubitemid 47040487)
33. O. Casanovas, D.J. Hicklin, G. Bergers Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309 (Pubitemid 41443415)
34. M.R. Kano, Y. Morishita, C. Iwata VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling J Cell Sci 118 2005 3759 3768 (Pubitemid 41309422)
35. L.J. Nissen, R. Cao, E.M. Hedlund Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis J Clin Invest 117 2007 2766 2777 (Pubitemid 47529608)
36. A. Sandler, R. Gray, M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
37. S.S. Ramalingam, S.E. Dahlberg, C.J. Langer Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599 J Clin Oncol 26 2008 60 65
38. M. Reck, J. von Pawel, P. Zatloukal Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL J Clin Oncol 27 2009 1227 1234
39. J.D. Patel, T.A. Hensing, A. Rademaker Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer J Clin Oncol 27 2009 3284 3289
40. M. Reck, J. von Pawel, P. Zatloukal Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Ann Oncol 21 2010 1804 1809
41. J.D. Hainsworth, L. Fang, J.E. Huang BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer J Thorac Oncol 6 2011 109 114
42. M.A. Socinski, C.J. Langer, J.E. Huang Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases J Clin Oncol 27 2009 5255 5261
43. G.A. Otterson, P.G. O'Connor, M. Lin Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy J Clin Oncol 27 2009 Abstract e19025
44. A.J. Wozniak, J. Garst, M. Jahanzeb Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): results from ARIES, a bevacizumab (BV) observational cohort study (OCS) J Clin Oncol 28 2010 Abstract 7618
45. A.C. Lockhart, M.L. Rothenberg, J. Dupont Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors J Clin Oncol 28 2010 207 214
46. Novello S, Ramlau R, Gorbunova VA, et al. Aflibercept in combination with docetaxel for second-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC): final results of a multinational placebo-controlled phase III trial (EFC10261-VITAL). Abstract associated with oral presentation at: 14th Biennial World Conference on Lung Cancer; July 3-7, 2011; Amsterdam, Netherlands. Abstract O43.06.
47. S.M. Wilhelm, C. Carter, L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109 (Pubitemid 39331023)
48. G. Scagliotti, S. Novello, J. von Pawel Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer J Clin Oncol 28 2010 1835 1842
49. J.H. Schiller, J.W. Lee, N.H. Hanna A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501 J Clin Oncol 26 2008 Abstract 8014
50. G.R. Blumenschein Jr, U. Gatzemeier, F. Fossella Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer J Clin Oncol 27 2009 4274 4280
51. T.J. Abrams, L.B. Lee, L.J. Murray SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Mol Cancer Ther 2 2003 471 478
52. M.A. Socinski, S. Novello, J.R. Brahmer Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer J Clin Oncol 26 2008 650 656 (Pubitemid 351264362)
53. S. Novello, G.V. Scagliotti, R. Rosell Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer Br J Cancer 101 2009 1543 1548
54. F. Hilberg, G.J. Roth, M. Krssak BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res 68 2008 4774 4782
55. G.J. Roth, A. Heckel, F. Colbatzky Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120) J Med Chem 52 2009 4466 4480
56. M. Reck, R. Kaiser, C. Eschbach A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer Ann Oncol 22 2011 1374 1381
57. P. Nikolinakos, J.V. Heymach The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies J Thorac Oncol 3 2008 S131 S134
58. G.D. Goss, A. Arnold, F.A. Shepherd Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study J Clin Oncol 28 2010 49 55
59. Site Committee Open/Closed/Planned/On Hold/Withdrawn Studies NCIC Clinical Trials Group [Web site] http://www.ctg.queensu.ca/public/Clinical- Trials/ph3-trial-accrual-closed.htm Accessed: August 11, 2011
60. S.M. Gadgeel, A. Wozniak, M.J. Edelman Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC) J Clin Oncol 27 2009 Abstract e19007
61. T.K. Choueiri Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors Curr Opin Investig Drugs 9 2008 658 671 (Pubitemid 351777169)
62. J.H. Schiller, T. Larson, S.H. Ou Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study J Clin Oncol 27 2009 3836 3841
63. W.J. van Heeckeren, J. Ortiz, M.M. Cooney Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 25 2007 2993 2995 (Pubitemid 47218042)
64. J.D. Hood, C.J. Meininger, M. Ziche VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells Am J Physiol 274 1998 1054 1058
65. S.E. Dahlberg, A.B. Sandler, J.R. Brahmer Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 J Clin Oncol 28 2010 949 954
66. P. Bono, H. Elfving, T. Utriainen Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma Ann Oncol 20 2009 393 394
67. H. Hurwitz, P.S. Douglas, J.P. Middleton Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV) J Clin Oncol 28 2010 Abstract 3039
68. B.P. Schneider, M. Wang, M. Radovich Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J Clin Oncol 26 2008 4672 4678
69. C. Gridelli, A. Rossi, P. Maione Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer Oncologist 14 2009 612 620
70. M.J. McKeage, J. von Pawel, M. Reck Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer Br J Cancer 99 2008 2006 2012
71. M.J. McKeage, M. Reck, M.B. Jameson Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer Lung Cancer 65 2009 192 197
72. P.N. Lara Jr, J.Y. Douillard, K. Nakagawa Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer J Clin Oncol 29 2011 2965 2971
73. Antisoma plc Antisoma announces outcome of ASA404 ATTRACT-2 trial [press release] Antisoma; November 11, 2010 http://www.antisoma.com/asm/media/press/ pr2010/2010-11-11/ Accessed: November 24, 2010
74. R.K. Jain, D.G. Duda, C.G. Willett Biomarkers of response and resistance to antiangiogenic therapy Nat Rev Clin Oncol 6 2009 327 338
75. A. Dowlati, R. Gray, A.B. Sandler Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study Clin Cancer Res 14 2008 1407 1412 (Pubitemid 351413922)
76. E.O. Hanrahan, H.Y. Lin, E.S. Kim Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer J Clin Oncol 28 2010 193 201
77. R.J. Motzer, M.D. Michaelson, B.G. Redman Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 16 24 (Pubitemid 46630489)
78. P. Delmotte, B. Martin, M. Paesmans VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis [in French] Rev Mal Respir 19 2002 577 584 (Pubitemid 35303646)
79. C. Bernaards, P. Hegde, D. Chen Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: analysis of phase III studies J Clin Oncol 28 2010 Abstract 10519
80. E.S. Kim, R.S. Herbst, J.J. Lee The BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination): personalizing therapy for lung cancer Presented at: 101st Annual Meeting of the American Association for Cancer Research Washington, DC April 17-21, 2010
81. R.S. Herbst Toxicities of antiangiogenic therapy in non-small-cell lung cancer Clin Lung Cancer 8 2006 S23 S30
82. H. Izzedine, C. Massard, J.P. Spano VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management Eur J Cancer 46 2010 439 448
83. A.B. Lima, L.T. Macedo, A.D. Sasse Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis PLoS One 6 2011 e22681
84. L. Crino, E. Dansin, P. Garrido Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study Lancet Oncol 11 2010 733 740
85. G. Giuliani, F. Grossi, M.F. de Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy Lung Cancer 69 Suppl 1 2010 S11 S17